A day after axing a study of SAB Biotherapeutics' COVID-19 antibody, the National Institutes of Health (NIH) has placed another arm of the trial on hold, this time for Synairgen’s inhaled medicine. Synairgen said Thursday that the study is temporarily paused "in light of the emergence of the Omicron variant." Source: Fierce Biotech 3/3/22